Renal Transplantation Dramatically Reduces IgA Anti-beta-2-glycoprotein I Antibodies in Patients with Endstage Renal Disease

Table 3

Characteristics of patients with or without persistent antibodies IgA aB2GPI after transplantation.

	Patients who negativice antibodies after; transplantation (𝑁=53)		Patients with persistent antibodies; IgA aB2GPI (𝑁=28)		𝑃 value
	𝑁/Mean	(%)/SE	𝑁/Mean	(%)/SE
Levels of IgA aB2GPI (U/mL)
Pretransplant	44,7	±7	91,4	±16,5	0,0133
Posttransplant	7,1	±0,6	69,6	±13,2	<0,0001
Difference pre-/posttransplant	−37,6	±7	−21,9	±12,7	0,2403
Pretransplant situation
Waiting time (months)	16,7	±2,4	21,9	±3,7	0,5570
Age (years)	53,5	±2,1	63,8	±2,3	0,0034
Previous transplants	4	(6,3%)	2	(7,1%)	0,7514
Induction treatment	42	(66,6%)	19	(67,8%)	0,8965
Timoglobuline	26	(41,2%)	8	(28,5%)	0,3571
Baxiliximab	16	(25,3%)	11	(39,2%)	0,2757
Etiology of endstage renal disease
Diabetic nephropathy	14	(22.2%)	10	(35.7%)	0.2756
Glomerular disease	6	(9.5%)	2	(7.1%)	0.9754
Nephroangiosclerosis	2	(3.2%)	1	(3.6%)	1,0000
Systemic Lupus Erythematosus	1	(1.6%)	0	(0.0%)	1,0000
Interstitial nephritis	4	(6.3%)	6	(21.4%)	0.0785
Polycystic kidney disease	8	(12.7%)	2	(7.1%)	0.6752
Others	5	(7.9%)	1	(3.6%)	0.7514
Undetermined	13	(20.6%)	6	(21.4%)	0.8466